Updated from 7:18 a.m.
Fovista combined with the currently approved drug Lucentis failed to improve the vision of patients with wet, age-related macular degeneration compared to Lucentis alone.
Ophthotech shares are down nearly 85% to $5.93 in Monday trading. The stock closed Friday at $38.77 per share.
Novartis (NVS) - Get Novartis AG Sponsored ADR Report licensed Fovista from Ophthotech in a bid to boost declining sales of Lucentis, which has been losing market share to Regeneron Pharmaceutical's (REGN) - Get Regeneron Pharmaceuticals, Inc. Report competing drug Eylea.
Fovista's failure removes a significant competitive overhang for Regeneron and Eylea, said RBC Capital Markets analyst Adnan Butt.
The combined analysis from the two phase III trials showed wet AMD patients treated with the Fovista-Lucentis combination therapy gained a mean of 10.24 letters on a standard eye chart at 12 months compared to a mean gain of 10.01 letters for patients receiving Lucentis alone.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.